Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial ...

Orman also has spotted some stock-market winners. On CNBC's "Fast Money" in late October 2023, she recommended Palantir Technologies (PLTR), Microsoft (MSFT), Amazon.com (AMZN), Shopify (SHOP) and ...

Although infection prevention is an essential part of every rheumatologist’s routine, balancing efficacy, risk and individual patient choices — all while contending with a seemingly constant flow of ...

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Michael R. Jackson's hit Broadway musical, A Strange Loop, was in part inspired by the crass way HIV was treated by Tyler ...